Clinical Trial NCT05744921

Trial

Regeneron – 2050 2021-004931-10 (NCT05744921)

Clinical trial ID

NCT05744921

Drug name

Pozelimab and Cemdisiran

Company:

Regeneron

Drug trade name

---

Clinicaltrials.gov

Learn more

Phase of study

3

Current status

Recruiting

Start

03/2023

Substance

Monoclonal antibody and RNAi

Research question

Safety, efficacy and tolerability of combination therapy

Delivery method of drug

s.c.

Frequency

Every four weeks

Clinical trial locations

Korea Canada Hungary India Italy Japan Malaysia Philippines Poland Romania Singapore Spain Taiwan Thailand Turkey